De Smedt, R., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., Goossens, S., Lammens, T., Van Roy, N., Touzart, A., Jenni, S., Tsai, Y.-C., Lovisa, F., Mussolin, L., Serafin, V., Van Nieuwerburgh, F., Deforce, D., Uyttebroeck, A., Tousseyn, T., Burkhardt, B., Klapper, W., De Moerloose, B., Benoit, Y., Macintyre, E., Bourquin, J.-P., Basso, G., Accordi, B., Bornhauser, B., Meijerink, J., Vandenberghe, P. and Van Vlierberghe, P. (2018) “Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma”, Haematologica. Pavia, Italy, 104(1), pp. e17-e20. doi: 10.3324/haematol.2018.199257.